These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24584077)

  • 1. A Hitchhiker's guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme.
    Sands MS
    Mol Ther; 2014 Mar; 22(3):483-484. PubMed ID: 24584077
    [No Abstract]   [Full Text] [Related]  

  • 2. From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery.
    Mäger I; Roberts TC; Wood MJ; El Andaloussi S
    Mol Ther; 2014 Mar; 22(3):485-486. PubMed ID: 24584078
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain.
    Meng Y; Sohar I; Sleat DE; Richardson JR; Reuhl KR; Jenkins RB; Sarkar G; Lobel P
    Mol Ther; 2014 Mar; 22(3):547-553. PubMed ID: 24394185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism.
    Meng Y; Wiseman JA; Nemtsova Y; Moore DF; Guevarra J; Reuhl K; Banks WA; Daneman R; Sleat DE; Lobel P
    Mol Ther; 2017 Jul; 25(7):1531-1543. PubMed ID: 28456380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tripeptidyl peptidase 1 in patients with late infantile neuronal ceroid lipofuscinosis].
    Contreras LM; Luengo WD; Zerpa N; Hernández JC; Chávez CJ; Ferrer SG
    An Pediatr (Barc); 2012 Mar; 76(3):148-52. PubMed ID: 22100780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses.
    Chang X; Huang Y; Meng H; Jiang Y; Wu Y; Xiong H; Wang S; Qin J
    Brain Dev; 2012 Oct; 34(9):739-45. PubMed ID: 22245569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of late-infantile neuronal ceroid lipofuscinosis using dried blood spot-based assay for TPPI enzyme activity: TPPI diagnostic assay from DBS.
    Gavin M; Khatoon S; Marchi EJ; Mevs CA; Bolton DC; Velinov MT; Junaid MA
    Clin Chim Acta; 2020 Aug; 507():62-68. PubMed ID: 32298681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal ceroid lipofuscinosis/Batten disease: the lysosomal proteinoses.
    Gupta P; Hofmann SL
    Mol Psychiatry; 2002; 7(5):434-6. PubMed ID: 12082556
    [No Abstract]   [Full Text] [Related]  

  • 9. A critical tryptophan and Ca2+ in activation and catalysis of TPPI, the enzyme deficient in classic late-infantile neuronal ceroid lipofuscinosis.
    Kuizon S; DiMaiuta K; Walus M; Jenkins EC; Kuizon M; Kida E; Golabek AA; Espinoza DO; Pullarkat RK; Junaid MA
    PLoS One; 2010 Aug; 5(8):e11929. PubMed ID: 20689811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Tracy CJ; Whiting RE; Pearce JW; Williamson BG; Vansteenkiste DP; Gillespie LE; Castaner LJ; Bryan JN; Coates JR; Jensen CA; Katz ML
    Exp Eye Res; 2016 Nov; 152():77-87. PubMed ID: 27637672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuronal ceroid-lipofuscinoses.
    Bennett MJ; Rakheja D
    Dev Disabil Res Rev; 2013; 17(3):254-9. PubMed ID: 23798013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.
    Ghosh A; Rangasamy SB; Modi KK; Pahan K
    J Neurochem; 2017 May; 141(3):423-435. PubMed ID: 28199020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel CLN2/TPP1 mutation in a patient with late infantile neuronal ceroid lipofuscinosis.
    Yu F; Liu XM; Chen YH; Zhang SQ; Wang K
    Neurol Sci; 2015 Oct; 36(10):1917-9. PubMed ID: 26032578
    [No Abstract]   [Full Text] [Related]  

  • 14. [Jansky-Bielschowsky disease].
    Saitoh S
    Ryoikibetsu Shokogun Shirizu; 2002; (37 Pt 6):252-4. PubMed ID: 12483874
    [No Abstract]   [Full Text] [Related]  

  • 15. Histochemical Demonstration of Tripeptidyl Aminopeptidase I.
    Dimitrova MB; Atanasova DY; Lazarov NE
    Methods Mol Biol; 2017; 1560():55-68. PubMed ID: 28155145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis.
    Sondhi D; Johnson L; Purpura K; Monette S; Souweidane MM; Kaplitt MG; Kosofsky B; Yohay K; Ballon D; Dyke J; Kaminksy SM; Hackett NR; Crystal RG
    Hum Gene Ther Methods; 2012 Oct; 23(5):324-35. PubMed ID: 23131032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I.
    Walus M; Kida E; Golabek AA
    Hum Mutat; 2010 Jun; 31(6):710-21. PubMed ID: 20340139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic late infantile neuronal ceroid lipofuscinosis in a Chinese patient.
    Ko CH; Kong CK; Chow TC; Lee KC
    Hong Kong Med J; 2001 Mar; 7(1):93-6. PubMed ID: 11406682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial genetic suppression of a loss-of-function mutant of the neuronal ceroid lipofuscinosis-associated protease TPP1 in Dictyostelium discoideum.
    Phillips JE; Gomer RH
    Dis Model Mech; 2015 Feb; 8(2):147-56. PubMed ID: 25540127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease.
    Wong LC; Hsu CJ; Lee WT
    Brain Dev; 2019 Oct; 41(9):817-819. PubMed ID: 31122803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.